Home Tirzepatide Tirzepatide vs Liraglutide
Tirzepatide vs Liraglutide
The first-generation option, still prescribed, still relevant in specific cases.
Liraglutide is a daily GLP-1 receptor agonist and the oldest of the injectable weight-management options. Reported mean weight reduction in its pivotal program was substantially lower than tirzepatide's in SURMOUNT-1, and it requires a daily rather than weekly injection.
It remains relevant in three situations: where it is the covered option, where a shorter-acting agent is clinically preferred, and where a patient has tolerated it and does not want to change.
Comparisons between agents that have not been tested head to head are cross-trial comparisons and are weaker evidence than a randomized comparison. This page labels which is which.
The daily injection question
Seven injections a week versus one is a real adherence difference over years, and adherence is the strongest predictor of outcome in this class. For most patients starting fresh, that alone argues for a weekly agent.
Where liraglutide still fits
A shorter half-life means the drug clears faster if it needs to be stopped, which occasionally matters clinically. Availability of a generic version in some markets has also changed its price position materially relative to the newer agents.
What the comparison is not
This is a cross-trial comparison, not a head-to-head. The populations, durations and endpoints differ. The direction of the difference is consistent, but the precise gap should not be quoted as though it came from a randomized comparison.
Tirzepatide vs Liraglutide: the shortest useful summary
Tirzepatide is a once-weekly injection titrated from 2.5 mg to a 15 mg ceiling in 2.5 mg steps at intervals of at least four weeks, producing roughly 15 to 21% mean weight reduction across the studied maintenance arms at 72 weeks and about 20% against semaglutide's 14% in the only head-to-head trial. It works while it is taken; the withdrawal evidence shows substantial regain after stopping. Compounded preparations cost from $133 a month and are not FDA-approved; brand product is approved and costs considerably more.
Those five facts decide most questions people arrive with. Everything else on this page is detail underneath them — which is worth reading before you spend $2,388 on a first year, but not worth confusing with the outline.
Tirzepatide vs Liraglutide: where to go next
If you have not chosen a program, price your expected maintenance dose with the projector rather than reading advertisements. If you have, check what it charges at 10 mg against the price-by-dose table. If you are struggling with side effects, the side-effect reference covers each one with reported frequencies and the red flags that need a clinician. And if a program has refused to name its pharmacy, the verification walkthrough explains why that single answer outranks any price difference.
Frequently asked questions
Is liraglutide cheaper?
In some markets generic availability has moved its price well below the newer branded agents. Compare on twelve-month cost at your dose.
Can I switch from liraglutide to tirzepatide?
Yes, with a fresh tirzepatide titration. There is no milligram conversion between the molecules.
People also ask about tirzepatide vs liraglutide
What is tirzepatide vs liraglutide?
Tirzepatide vs liraglutide is covered in full on this page, with the clinical detail drawn from the tirzepatide prescribing information and the published SURMOUNT and SURPASS trial program, and any price figures drawn from our tracked dataset and dated to their last verification.
Does tirzepatide vs liraglutide apply to compounded tirzepatide as well as Zepbound?
The molecule is the same, so the clinical content applies to both. What differs is regulatory status, dose metering and price: compounded preparations are not FDA-approved, arrive as a multi-dose vial you measure yourself, and cost a fraction of the brand routes.
How much does tirzepatide vs liraglutide cost per month in 2026?
Compounded tirzepatide runs from $133 per month at the entry dose across the 21 compounded programs we track. At a 10 mg maintenance dose the cheapest tracked route is Oak Longevity at $199 per month, or about $2,388 for a first year on the standard escalation. Brand Zepbound through manufacturer self-pay sits well above that and pharmacy retail well above again. Verified 2026-08-05.
Is tirzepatide vs liraglutide FDA-approved?
Brand tirzepatide (Zepbound and Mounjaro) is FDA-approved. Compounded tirzepatide is not: FDA does not approve compounded drugs and does not review them for safety, effectiveness or quality before they are marketed. The active molecule is the same; the regulatory review is not.
Sources
- SURMOUNT-1 — tirzepatide once weekly for the treatment of obesity, NCT04184622.
- SURMOUNT-5 — tirzepatide versus semaglutide in adults with obesity, NCT05822830.
- US prescribing information for tirzepatide (Zepbound and Mounjaro), Eli Lilly and Company — dosing, storage, warnings and contraindications.
- US Food and Drug Administration, human drug compounding: compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality before marketing.
- Full source ledger — every primary source with a live link, what it supports, the date we read it, and the claims we deliberately do not source.